A phase II trial of docetaxel and irinotecan (DI) in children and young adults with recurrent or refractory Ewing sarcoma family of tumor (ESFT).
Jong Hyung Yoon
No relevant relationships to disclose
Hyeon Jin Park
No relevant relationships to disclose
Byung-Kiu Park
No relevant relationships to disclose